{
    "clinical_study": {
        "@rank": "28472", 
        "arm_group": [
            {
                "arm_group_label": "Argatroban group", 
                "arm_group_type": "Experimental", 
                "description": "Argatroban in patients undergoing load 250\u03bcg/kg, followed by 15\u03bcg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day"
            }, 
            {
                "arm_group_label": "non-argatroban treated group", 
                "arm_group_type": "Experimental", 
                "description": "Patients in control group will receive Unfractionated heparin treatment"
            }
        ], 
        "brief_summary": {
            "textblock": "Argatroban is a selective thrombin inhibitor, and previous study had suggested that\n      argatroban use post percutaneous coronary intervention could potentially prevent\n      reocclusion. But there has no study on large sample of argatroban treated restenosis\n      vertebral artery stenting. This study will test the safety and efficacy of the argatroban on\n      prevent Occlusion and Restenosis in patients with Extracranial vertebral Artery Stenting."
        }, 
        "brief_title": "Argatroban for Preventing Occlusion and Restenosis After Extracranial Vertebral Artery Stenting", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "CVD", 
        "detailed_description": {
            "textblock": "The risk of restenosis post intracranial and extracranial artery stenting is 20-40%,\n      therefore, in the past, aspirin and clopidogrel were performed as anticoagulant therapy post\n      stenting.But this treatment had limited effectiveness upon restenosis. Argatroban is a\n      selective thrombin inhibitor, and previous study had suggested that argatroban use post PCI\n      could potentially prevent reocclusion. But there has no study on large sample of argatroban\n      treated Occlusion and Restenosis Extracranial vertebral Artery Stenting. This study will\n      test the safety and efficacy of the argatroban on prevent Occlusion and Restenosis in\n      patients with Extracranial vertebral Artery Stenting."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  For Extracranial vertebral Artery lesion, stenting was considered for symptomatic\n             stenosis\u226550% or asymptomatic stenosis\u226570%;\n\n          -  Successfully had intracranial or extracranial artery stenting.\n\n        Exclusion Criteria:\n\n          -  Evidence of hemorrhagic brain infarction, intracranial and extracranial hematoma, or\n             intraventricular hemorrhage, or Gastrointestinal ulcers in 3 months\n\n          -  Hypersensitivity to contrast agent\n\n          -  Malignant hypertension\n\n          -  Difficult to perform the vertebral artery stenting\n\n          -  Severe hepatic or cardiac disorders, infectious disorders, dehydration, etc.\n\n          -  Difficult to hand follow-up visit"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01980316", 
            "org_study_id": "JLH3"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Argatroban group", 
                    "non-argatroban treated group"
                ], 
                "description": "Argatroban in patients undergoing load 250\u03bcg/kg, followed by 15\u03bcg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day", 
                "intervention_name": "Argatroban", 
                "intervention_type": "Drug", 
                "other_name": "Argatroban"
            }, 
            {
                "arm_group_label": [
                    "Argatroban group", 
                    "non-argatroban treated group"
                ], 
                "description": "Patients in control group will receive Unfractionated heparin treatment", 
                "intervention_name": "non-argatroban treated group", 
                "intervention_type": "Drug", 
                "other_name": "Unfractionated heparin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium heparin", 
                "Argatroban", 
                "Heparin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Argatroban", 
            "Extracranial vertebral Artery Stenting", 
            "restenosis"
        ], 
        "lastchanged_date": "February 28, 2014", 
        "location": {
            "contact": {
                "email": "xfliu2@vip.163.com", 
                "last_name": "Xinfeng Liu, MD", 
                "phone": "(++) 86- (+) -25-84801861"
            }, 
            "facility": {
                "address": {
                    "city": "Nanjing", 
                    "country": "China", 
                    "state": "Jiangsu", 
                    "zip": "210009"
                }, 
                "name": "Department of Neurology, Jinling Hospital, Nanjing University School of Medicine"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 4 Study of Argatroban for Preventing Restenosis After Extracranial Vertebral Artery Stenting", 
        "other_outcome": {
            "measure": "Various adverse effects", 
            "safety_issue": "Yes", 
            "time_frame": "at half a year"
        }, 
        "overall_contact": {
            "email": "xfliu2@vip.163.com", 
            "last_name": "Xinfeng Liu, MD", 
            "phone": "(++) 86- (+) -25-84801861"
        }, 
        "overall_official": {
            "affiliation": "Department of Neurology, Jinling Hospital, Nanjing University School of Medicine", 
            "last_name": "Xinfeng Liu, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Stenosis detected by DSA(digital subtraction angiography),CTA(CT angiography)or MRA(MR angiography)was measured according to NASCET(North American Symptomatic Carotid Endarterectomy Trial)method.Concretely, NASCET stenosis is calculated from the ratio of the linear luminal diameter of the narrowest segment of the diseased portion of the artery to the diameter of the artery beyond any poststenotic dilatation: NASCET=(1-md/C)\u00d7100%", 
            "measure": "restenosis", 
            "safety_issue": "Yes", 
            "time_frame": "at half a year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01980316"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Jinling Hospital, China", 
            "investigator_full_name": "Xinfeng Liu", 
            "investigator_title": "Argatroban for Preventing Restenosis After Extracranial vertebral Artery Stenting", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "NIHSS and mRS are widely used stroke deficit assessment tools. Most clinical stroke-related trials require a baseline and outcome severity assessment. The baseline of mRS is rank 0, NIHSS 0; the severity of mRS is 6, NIHSS 42. AS many patients have one or more strokes before they perform stenting, this study selected NIHSS and mRS as the supplementary materials to estimate the stroke deficit of patients and to reflect the therapeutic effect and safety of stenting and argatroban therapy. These two scales are performed according to the guidance before and after stenting and argatroban therapy.", 
            "measure": "NIHSS, mRS", 
            "safety_issue": "Yes", 
            "time_frame": "at half a year"
        }, 
        "source": "Jinling Hospital, China", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xinfeng Liu", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}